Benylin

Benylin is a brand of over-the-counter medicines for cough, cold and flu symptoms. The brand originated in Canada and is marketed in multiple countries, including Canada and the United Kingdom. Its portfolio includes liquid and solid dosage forms, with formulations varying by market and product. Depending on the specific medicine, active ingredients may include dextromethorphan, guaifenesin, pseudoephedrine, paracetamol (acetaminophen), and, in some products, codeine. A prominent part of the portfolio is Benylin DM, whose name refers to dextromethorphan, an antitussive used to suppress certain types of cough. Other Benylin products combine cough treatment with medicines intended to address congestion, fever, pain, or mucus. Because formulations and regulatory classifications differ between countries, the composition and permitted uses of products sold under the Benylin name are not uniform across markets. The brand became part of Pfizer's consumer-health business before being transferred to Johnson & Johnson in 2008. Following the separation of Johnson & Johnson's consumer-health activities into Kenvue, Benylin became a Kenvue brand. The brand has had a particularly visible presence in the United Kingdom, where it was reported as one of the country's biggest-selling branded over-the-counter medicines in 2016, with reported sales of £36.8 million for that year. No current consolidated global sales figure is established in the available reference material. Benylin's positioning is that of a mainstream, pharmacy and retail-distributed consumer-health brand focused on accessible symptom relief rather than prescription treatment. Its principal competitive context is the broad over-the-counter cough, cold and flu category, where product choice is driven by symptom type, formulation, active ingredients, age restrictions, and national rules governing medicines containing substances such as codeine or pseudoephedrine.

Benylin is a Canadian-origin consumer-health brand whose name is used for a range of medicines intended to relieve cough, cold, and flu symptoms. The brand is not a single formulation: products sold under the name differ by country and by indication, and can be presented as liquids or solid dosage forms. This market-by-market variation is important because national medicine regulations govern the ingredients, claims, age limits, and supply conditions for each product. The portfolio includes products centered on cough suppression as well as combination medicines for broader cold symptoms. Benylin DM is associated with dextromethorphan, an ingredient used as a cough suppressant. Other formulations may contain guaifenesin for mucus-related symptoms, pseudoephedrine for nasal congestion, or paracetamol (acetaminophen) for pain and fever. Some products in the wider Benylin range contain codeine, which has uses relating to pain and cough and is subject to additional controls in many jurisdictions. The presence of these different active ingredients means that the Benylin name covers a family of products rather than one standardized global recipe. The brand was sold by Pfizer to Johnson & Johnson in 2008. This transaction placed Benylin within Johnson & Johnson's consumer-health operations. In the subsequent corporate separation of those activities, Benylin became part of Kenvue's brand portfolio. The available reference material does not establish a precise original founding year, a named founder, or a specific manufacturing headquarters. Benylin has maintained a notable retail and pharmacy presence in the United Kingdom as well as in Canada and other markets. In 2016, it was reported as one of the biggest-selling branded over-the-counter medicines in the United Kingdom, with sales of £36.8 million. That figure is a historical United Kingdom sales figure rather than a current global revenue measure. The brand's commercial role is centered on consumer self-care: it offers readily available symptom-relief products for common respiratory illnesses, with consumers selecting among products according to symptoms and active ingredients. The principal historical turning point documented in the available material is the change in ownership from Pfizer to Johnson & Johnson in 2008, followed later by the placement of the brand within Kenvue. Beyond those ownership changes and the 2016 United Kingdom sales reference, detailed information about advertising campaigns, individual product launch dates, leadership, manufacturing sites, and country-specific regulatory events is not established by the supplied sources.

• 2016

  Strong United Kingdom over-the-counter sales

  [1]Benylinen.wikipedia.org

  Benylin was reported as one of the biggest-selling branded over-the-counter medicines in the United Kingdom, with sales of £36.8 million.

• 2008

  Transfer from Pfizer to Johnson & Johnson

  [1]Benylinen.wikipedia.org

  Pfizer sold Benylin to Johnson & Johnson, moving the brand into Johnson & Johnson's consumer-health business.

• Kenvue ownership

  [1]Benylinen.wikipedia.org

  Benylin became part of Kenvue's consumer-health brand portfolio following the separation of Johnson & Johnson's consumer-health activities.

Mainstream over-the-counter cough, cold and flu relief brand

• Cough suppressant

  Benylin DM

  A Benylin product family associated with dextromethorphan, an antitussive used to suppress certain coughs. Products using the Benylin DM name may differ in formulation, dosage form, approved indications, and labeling by country.

• Cough medicine

  Benylin cough syrups

  Liquid cough medicines sold under the Benylin name. The range includes formulations designed for different cough types and may use ingredients such as dextromethorphan, guaifenesin, or codeine depending on the specific product and market.

• Cold and flu medicine

  Benylin cold and flu medicines

  Combination products intended to address multiple cold or flu symptoms. Depending on local availability, formulations may combine cough treatment with ingredients for congestion, pain, fever, or mucus.

• 2008

  Change of brand ownership from Pfizer to Johnson & JohnsonM&A

  Background

  Benylin was part of Pfizer's consumer-health portfolio before Pfizer sold the brand to Johnson & Johnson.

  Action taken

  Johnson & Johnson acquired the brand and incorporated it into its consumer-health activities.

  Aftermath

  The brand later became part of Kenvue following the separation of Johnson & Johnson's consumer-health business.

  Source

• Continuation as a multi-formulation cough and cold portfolioStrategy

  Background

  Benylin products are marketed in liquid and solid forms and use different active-ingredient combinations across markets.

  Action taken

  The brand has maintained a broad over-the-counter portfolio covering cough suppression, mucus relief, congestion, pain, and fever-related symptoms.

  Aftermath

  Benylin remains positioned as a mainstream consumer-health brand, although individual product compositions and regulatory status vary by country.

  Source

1. 1Benylinen.wikipedia.org